Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis

European Journal of Clinical Pharmacology

Volumn 66, Issue 10, 2010, Pages 1055-1063

  Bertino, Gaetano ^a   Ardiri, Annalisa ^a   Boemi, Patrizia Maria ^a   Calvagno, Giuseppe Stefano ^a   Ruggeri, Irene Maria ^b   Speranza, Annalisa ^a   Santonocito, Maria Milena ^a   Ierna, Dario ^a   Bruno, Cosimo Marcello ^a   Valenti, Maria ^a   Boemi, Roberta ^a   Naimo, Simona ^a   Neri, Sergio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b ARNAS Civic Hospital   (Italy)

Author keywords

Epoetin alpha; Genotype 1b HCV related chronic hepatitis; Peg interferon alpha 2A; Ribavirin

Indexed keywords

ANTIDEPRESSANT AGENT; HEMOGLOBIN; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

ADULT; ANEMIA; ANXIETY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; ANEMIA, HYPOCHROMIC; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPOETIN ALFA; FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77957673661     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0868-4     Document Type: Article

References (58)

1. DB Strader T Wright DL Thomas, et al. 2004 American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C Hepatology 39 4 1147 1171 10.1002/hep.20119 15057920
2. AL Zignego C Giannini C Ferri 2007 Hepatitis C virus-related lymphoproliferative disorders: an overview World J Gastroenterol 13 17 2467 2478 1:CAS:528:DC%2BD2sXotl2ltbw%3D 17552031 Review
3. A Craxì G Laffi AL Zignego 2008 Hepatitis C virus (HCV) infection: a systemic disease Mol Aspects Med 29 1-2 85 95 10.1016/j.mam.2007.09.017 18177700
4. MP Manns JG McHutchison SC Gordon, et al. 2001 Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 958 956 1:CAS:528:DC%2BD3MXntF2qtb8%3D 10.1016/S0140-6736(01)06102-5 11583749
5. MW Fried ML Shiffman KR Reddy, et al. 2002 Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975 982 1:CAS:528:DC%2BD38Xnt12rtb0%3D 10.1056/NEJMoa020047 12324553
6. SJ Hadziyannis S HJr TR Morgan, et al. 2004 PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346 355 1:CAS:528:DC%2BD2cXitlOktrg%3D 14996676
7. ML Shiffman AM Di Bisceglie KL Lindsay, et al. 2004 Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon alpha-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 4 1015 1023 1:CAS:528:DC%2BD2cXkt1Krsbc%3D 10.1053/j.gastro.2004.01.014 15057741
8. S Leiner 2007 Peginterferon and ribavirin for hepatitis C N Engl J Med 356 12 1270 1:CAS:528:DC%2BD2sXjtl2ls78%3D 17380577
9. SJ Hadziyannis JS Koskinas 2004 Differences in epidemiology, liver disease and treatment response among HCV genotypes Hepatology Research 29 3 129 135 10.1016/j.hepres.2004.02.011 15203075
10. E Formann W Jessner L Bennett, et al. 2003 Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1 J Viral Hepat 10 4 271 276 1:STN:280: DC%2BD3szksVOqtQ%3D%3D 10.1046/j.1365-2893.2003.00446.x 12823593
11. G Saracco M Rizzetto 1996 Predictors of response to interferon therapy Dig Dis Sci 41 12 Suppl 115S 120S 1:STN:280:DyaK2s7kvVOquw%3D%3D 10.1007/BF02087886 9011468
12. MG Neuman JP Benhamou M Martinot, et al. 1999 Predictors of sustained response to alpha interferon therapy in chronic hepatitis C Clinical biochemistry. 32 7 537 545 1:CAS:528:DC%2BD3cXitFSmsA%3D%3D 10.1016/S0009- 9120(99)00053-3 10614716
13. MP Manns 2004 Adherence to combination therapy: influence on sustained virologic response and economic impact Gastroenterol Clin N Am 33 1 Suppl S11 S24 10.1016/j.gtc.2003.12.003
14. MW Russo MW Fried 2003 Side effects of therapy for chronic hepatitis C Gastroenterology 124 6 1711 1719 10.1016/S0016-5085(03)00394-9 12761728
15. L De Franceschi G Fattovich F Turrini, et al. 2000 Hemolitic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection Hepatology 31 997 1004 10.1053/he.2000.5789 10733558
16. P Rendo A Rosso F Gomez, et al. 2000 Anaemia in patients with chronic hepatitis C treated with ribavirin and peg-interferon Antivir Ther 5 suppl 1 C96
17. DT Dieterich JL Spivak 2003 Hematologic disorders associated with hepatitis C virus infection and their management Clin Infect Dis 37 4 533 541 1:CAS:528:DC%2BD3sXns1eisr0%3D 10.1086/376971 12905138
18. M Peck-Radosavljevic M Wichlas M Homoncik-Kraml, et al. 2002 Rapid suppression of haematopoiesis by standard or pegylated interferon alpha Gastroenterology 123 141 151 1:CAS:528:DC%2BD38Xmt1aiu7Y%3D 10.1053/gast.2002. 34175 12105843
19. P Golia AH Talal IM Jacobs, et al. 2003 A preliminary study of growth factor versus dose reduction for peg-interferon alpha-2b and ribavirin associated neutropenia and anemia in HCV infected patients Gastroenterology 124 A766 10.1016/S0016-5085(03)83872-6
20. K Lindahl R Schvarcz A Bruchfeld, et al. 2004 Evidence that plasma concentration rather than dose per kilogram body weight predict ribavirin induced anemia J Viral Hepat 11 84 87 1:STN:280:DC%2BD2c%2FotFKrsQ%3D%3D 10.1046/j.1365-2893.2003.00475.x 14738562
21. KR Reddy ML Shiffman TR Morgan, et al. 2007 Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alpha 2a/ribavirin treatment Clin Gastroenterol Hepatol 5 124 129 1:CAS:528:DC%2BD2sXitVCmsbY%3D 10.1016/j.cgh.2006.10.008 17196435
22. JP Ong ZM Younossi 2004 Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia Cleve Clin J Med 71 Suppl 3 S17 S21 10.3949/ccjm.71.Suppl-3.S17 15468613 Review
23. KV Kowdley 2005 Hematologic side effects of interferon and ribavirin therapy J Clin Gastroenterol 39 1 Suppl S3 S8 1:CAS:528:DC%2BD2cXhtVKrtbbK 10.1097/01.mcg.0000145494.76305.11 15597025 Review
24. M Schmid A Kreil W Jessner, et al. 2005 Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens Gut 54 7 1014 1020 1:CAS:528:DC%2BD2MXmsFKqtrk%3D 10.1136/gut.2004.057893 15951552
25. L Sharvadze T Tsertsvadze N Gochitashvili, et al. 2006 IFN/RBV treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C Georgian Med News 137 62 65 16980747
26. AH Talal K Weisz T Hau, et al. 2001 A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha Am J Gastroenterol 96 9 2802 2804 1:STN:280:DC%2BD3MritFCisg%3D%3D 11569724
27. DT Dieterich R Wasserman N Bräu, et al. 2003 Once-weekly epoetin alpha improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alpha Am J Gastroenterol 98 11 2491 2499 1:CAS:528:DC%2BD3sXpt1Sgu7Y%3D 14638354
28. N Bräu 2004 Epoetin alpha treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C J Viral Hepat 11 3 191 197 10.1111/j.1365-2893.2004.00506.x 15117320 Review
29. V Balan D Schwartz GY Wu, et al. 2005 HCV Natural History Study Group. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin The American journal of gastroenterology 100 2 299 307 1:CAS:528:DC%2BD2MXisVeitL4%3D 10.1111/j.1572-0241.2005.40757.x 15667486
30. NH Afdhal DT Dieterich PJ Pockros, et al. 2004 Proactive Study Group. Epoetin alpha maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126 5 1302 1311 1:CAS:528:DC%2BD2cXksF2qtLg%3D 10.1053/j.gastro.2004.01.027 15131791
31. PJ Pockros ML Shiffman ER Schiff, et al. 2004 PROACTIVE Study Group. Epoetin alpha improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 6 1450 1458 1:CAS:528:DC%2BD2MXhslaguw%3D%3D 10.1002/hep.20482 15565613
32. S Lee J McHutchinson B Francis, et al. 1992 Improved detection of antibodies to hepatitis C virus using a second generation ELISA Adv Exp Med Biol 312 183 189 1:CAS:528:DyaK38XlvV2ksrw%3D 1381139
33. S Kawai O Yokosuka F Imazeki, et al. 2002 Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level J Med Virol 68 3 343 351 1:CAS:528:DC%2BD38XotFKiu70%3D 10.1002/jmv.10209 12226820
34. P Simmonds 1995 Variability of hepatitis C virus Hepatology 21 570 583 1:CAS:528:DyaK2MXkt1ChurY%3D 10.1002/hep.1840210243 7531173
35. P Simmonds A Alberti HJ Halter, et al. 1995 A proposed system for the nomenclature of hepatitis C viral genotypes Hepatology 22 2 418 425
36. PM Bayer B Fabian W Hübl 2001 Immunofluorescence assays (IFA) and enzyme-linked immunosorbent assays (ELISA) in autoimmune disease diagnostics-technique, benefits, limitations and applications Scand J Clin Lab Invest Suppl 235 68 76 1:STN:280:DC%2BD3Mnms1yrtA%3D%3D 11712695
37. P Mikosch HJ Gallowitsch E Kresnik, et al. 1997 Influence of human anti-mouse antibodies on thyrotropin in-vitro analysis: a comparison of 6 thyrotropin IRMA kits Eur J Clin Chem Clin Biochem 35 11 881 883 1:CAS:528:DyaK2sXnsFOntrs%3D 9426349
38. P Bedossa T Poynard 1996 An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 24 2 289 293 1:STN:280:DyaK28zhvFClug%3D%3D 10.1002/hep.510240201 8690394
39. Y Deugnier R Moirand P Brissot, et al. 1999 Iron in the era of molecular biology Pathol Biol 47 9 938 944 1:CAS:528:DC%2BD3cXit1Cntw%3D%3D 10609274
40. P Adams P Brissot LW Powell 2000 EASL International Consensus Conference on Haemochromatosis J Hepatol 33 3 485 504 1:STN:280:DC%2BD3cvmsVygtw%3D%3D 10.1016/S0168-8278(01)80874-6 11020008
41. JG Mchutchison M Manns K Patel, et al. 2002 Adherence to combination therapy enhances sustained response in genotype 1 infected patients with chronic hepatitis C Gastroenterology 123 1061 1069 1:CAS:528:DC%2BD38Xotl2gurk%3D 10.1053/gast.2002.35950 12360468
42. K Lindahl L Stahle A Bruchfeld, et al. 2005 High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C Hepatology 41 2 275 279 1:CAS:528:DC%2BD2MXhsVansbg%3D 10.1002/hep.20563 15660393
43. ML Yu CY Dai JF Huang, et al. 2008 Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure Hepatology 48 3 1019 1020 10.1002/hep.22434 18756469
44. P Ferenci MW Fried ML Shiffman, et al. 2005 Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alpha-2a (40 KD)/ribavirin J Hepatol 43 3 425 433 1:CAS:528: DC%2BD2MXntVCkurY%3D 10.1016/j.jhep.2005.04.009 15990196
45. VG Bain SS Lee K Peltekian, et al. 2008 Canadian PEGASYS Study Group. Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin Aliment Pharmacol Ther 28 1 43 50 1:CAS:528:DC%2BD1cXovFelsbg%3D 10.1111/j.1365-2036. 2008.03705.x 18397386
46. JG McHutchison MP Manns DL Longo 2006 Definition and management of anemia in patients infected with hepatitis C virus Liver Int 26 4 389 398 10.1111/j.1478-3231.2006.01228.x 16629641 Review
47. NH Afdhal 2004 Role of epoetin alpha in maintaining ribavirin dose Gastroenterol Clin North Am 33 1 Suppl S25 S35 10.1016/j.gtc.2003.12.002 15081101
48. JG McHutchison MP Manns RSJr Brown, et al. 2007 Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy Am J Gastroenterol 102 4 880 889 1:CAS:528:DC%2BD2sXltlOgsLY%3D 10.1111/j.1572-0241.2007.01139.x 17397412 Review
49. T Thevenot V Di Martino F Lunel-Fabiani, et al. 2006 Complementary treatments of chronic viral hepatitis C Gastroentérol Clin Biol 30 2 197 214 10.1016/S0399-8320(06)73154-2 16565651 Review
50. ML Shiffman J Salvatore S Hubbard, et al. 2007 Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha Hepatology 46 2 371 379 1:CAS:528:DC%2BD2sXhtVSisb%2FM 10.1002/hep.21712 17559152
51. LI Backus DB Boothroyd BR Philips, et al. 2007 Predictors of response of US veterans to the treatment for the hepatitis C virus Hepatology 46 37 47 1:CAS:528:DC%2BD2sXosVyltrk%3D 10.1002/hep.21662 17567830
52. Cash WJ, Patterson K, Callender ME et al. Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients. J Viral Hepat. 2009 Oct 11.
53. RA Del Rio AB Post ME Singer 2006 Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy Hepatology 44 6 1598 1606 10.1002/hep.21409 17133490
54. BM Spiegel K Chen CF Chiou, et al. 2005 Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis Clin Gastroenterol Hepatol 3 10 1034 1042 1:CAS:528:DC%2BD2MXhtFyltLfO 10.1016/S1542-3565(05)00695-6 16234051
55. EB Devine JT Cross KV Kowdley, et al. 2007 The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin Curr Med Res Opin 23 6 1463 1472 1:CAS:528:DC%2BD2sXosF2isL0%3D 10.1185/030079907X188189 17559739
56. N Kontorinis K Agarwal DT Dieterich 2004 Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin Rev Gastroenterol Disord 4 Suppl 1 S39 S47 15184822 Review
57. ZM Younossi FH Nader C Bai, et al. 2008 A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment J Viral Hepat 15 5 370 378 1:STN:280: DC%2BD1c3itFSqtw%3D%3D 10.1111/j.1365-2893.2007.00956.x 18194172
58. T Thévenot JF Cadranel V Di Martino, et al. 2007 A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C Hepatology 45 2 377 383 10.1002/hep.21517 17256721